Updates in Targeted Therapies for ALK+ and ROS1+ NSCLC from ESMO 2024 - Episode 6

The TRUST-II Study of Taletrectinib in ROS1+ Advanced NSCLC

,

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.